New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
07:32 EDTPOZNPOZEN submits PA8140/PA32540 Phase 1 final study report
POZEN announced that they have submitted the final study report for the Phase 1 study comparing the pharmacokinetic profile of the omeprazole component of PA8140 tablets to that of PA32540 tablets as agreed with the U.S. Food and Drug Administration.
News For POZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 23, 2015
09:07 EDTPOZNPOZEN, Tribute provide update on pending combination
POZEN and Tribute Pharmaceuticals Canada provided an update on their pending combination transactions. The companies have reviewed the recent guidance from the U.S. Treasury's Notice 2015-79 issued on November 19 and its potential impact on the proposed transaction. POZEN and Tribute remain committed to combining their respective businesses and are considering a Canadian domicile for Aralez Pharmaceuticals, the new parent entity for the combined companies. With the planned business operations in Ireland, Canada and the United States, the Canadian domicile offers substantially similar financial, tax and competitive advantages to an Irish domicile, and will benefit from Tribute's business foundation and strong presence in Canada where Tribute was incorporated and from where it has always operated. The parties further believe that a Canadian domicile will be in compliance with the new Treasury Department Guidance and are working diligently and expeditiously on an alternative transaction structure that would be in the best interest of their respective securityholders, and the parties are further considering the Treasury Department Guidance as they continue to arrive at this alternative transaction structure.
November 19, 2015
10:11 EDTPOZNHigh option volume stocks

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use